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The Society for Vascular Surgery considers the placement and maintenance of arteriovenous hemodialysis access to be an
important component of any vascular surgery practice. Therefore, the Society has long been involved in setting the
standards for the management of arteriovenous access. Formulating clinical recommendations in this area is the latest
effort by the Society to improve the management of arteriovenous access on a national level. To provide an unbiased study
of the evidence and to help in formulating the recommendations, the Society used the Knowledge and Encounter
Research (KER) Unit of the Mayo Clinic College of Medicine, Rochester, Minn, to review the available evidence and
advise a multidisciplinary group of access surgeons and nephrologists in formulating the clinical recommendations. To
review the evidence, randomized and observational study designs were both considered. Whenever possible, systematic
reviews and meta-analyses of the literature were used because, compared with individual studies, they generate more
precise estimates of treatment effects and their results are applicable to a wider range of patients. On behalf of the Society,
the group issued its recommendations following the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) format; this format disentangles the strength of recommendations from the quality of the evidence
and encourages statements about the underlying values and preferences relevant to the particular recommendation. The
recommendations are classified as strong (denoted by the phrase “we recommend”) or weak (denoted by the phrase “we
suggest”); and the quality of evidence is classified as high, moderate, low, or very low. These recommendations are not
meant to supersede clinical judgment; rather, they should be used as a guide for the practicing surgeon and nephrologist
as the decision is being made for the placement and subsequent procedures and management of arteriovenous
hemodialysis access are being considered. (J Vasc Surg 2008;48:26S-30S.)The Society for Vascular Surgery undertook the task of
developing evidence-based guidelines to assist patients and
clinicians in the process of decision making. To provide
better understanding of these guidelines and facilitate their
integration into daily practice, we present the method-
ologic framework that guideline developers have used to
formulate their recommendations. In this supplement,
practice guidelines for arteriovenous hemodialysis access
and the study of the evidence available in this field are
included. In this article, we discuss the evaluation and
synthesis of research evidence and the formulation of clear
and helpful clinical practice recommendations using the
vascular access reviews as examples.
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26SUSING RESEARCH EVIDENCE TO
FORMULATE RECOMMENDATIONS
Randomized controlled trials (RCTs) are the only
study design known to balance known and unknown prog-
nostic risk factors between study arms. Hence, RCTs are
considered the gold standard study design to evaluate the
effectiveness of therapeutic and diagnostic interventions.
However, not all randomized trials offer similarly strong
inferences because trialists may or may not use the various
measures intended to reduce the risk of bias, such as allo-
cation concealment, blinding, and the intention-to-treat
principle. For instance, when the Society for Vascular Sur-
gery evaluated the efficacy of vascular access surveillance,
only three of the 10 relevant RCTs protected randomiza-
tion by assuring that the person assigning patients to a
study arm was unaware of the randomization sequence, a
procedure called allocation concealment. This procedure
usually requires the use of central randomization (eg, the
investigator called a central location with patient character-
istics and received the arm allocation) or the use of sealed,
numbered, and opaque envelopes.1 Patients and surgeons
were appropriately not blinded in these trials; however, data
collectors and researchers ascertaining the outcomes could
have been blinded to reduce bias; the former was done in
five of 10 RCTs and the latter was done in only one RCT.
In the comparison between autogenous and prosthetic
accesses, it was unclear whether trials did not report or did
not adhere to the intention-to-treat principle, by which
researchers set up procedures and resources to keep ran-
domized participants in the arm to which they were ran-
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inferences from these trials need to be interpreted in the
context of the described methodologic limitations.
Moreover, the evaluation of surgical interventions pre-
sents challenges to the use of the randomized trials. Pa-
tients are reluctant to be randomized to procedures that
may be associated with permanent consequences or scars,
blinding surgeons and sham surgeries are often unfeasible,
and the duration of required follow-upmay be too long and
impractical for RCTs.2 As a consequence, evidence-based
surgeons have relied extensively on observational studies to
this point: only 3.4% of all publications in the leading
surgical journals are RCTs, and more than half of these
RCTs compared medical therapies in surgical patients
rather than alternative surgical procedures or surgical vs
medical or radiologic interventions.3
Recent innovations in the design of surgical trials may
overcome some of the limitations of traditional RCTs in
surgery, provide the bias protection that randomization
offers, and gain the ability to make strong inferences about
the efficacy of surgical interventions. An example of these
innovations is the expertise-based RCT. Whereas partici-
pants in conventional RCTs are randomized to one of two
interventions (A or B) and individual clinicians give inter-
vention A to some participants and B to others, participants
in expertise-based RCTs are randomized to clinicians with
expertise in intervention A or clinicians with expertise in
intervention B and the clinicians perform only the proce-
dure they are expert in.4 Trials of carotid endarterectomy
performed by vascular surgeons vs stenting performed by
interventional radiologists are examples of expertise-based
RCTs.
Observational studies are unlikely to provide the same
degree of protection against bias in ascertainment of the
efficacy of interventions compared with high-quality random-
ized trials. Their quality can be improved, however, when
investigators include measures aimed at reducing bias. Some
of thesemeasures (parallel to those that enhance the quality of
randomized trials) include selecting adequate populations,
making them appropriately comparable bymeans ofmatching
or statistical adjustment by key predictors of outcome, ensur-
ing adequate ascertainment of the exposures and outcomes at
baseline, planning long enough follow-up to allow time for
critical outcomes to develop, and blinding the assessment of
outcomes in both groups.5,6
Hence, in developing clinical practice guidelines for the
Society for Vascular Surgery, we considered evidence gen-
erated by both study designs: RCTs and observational
studies that included concurrent comparison cohorts. In
addition, it is important to recognize the inherent limita-
tions of both designs when applied to surgical interventions
in that surgical outcomes are often influenced by other
factors such as the surgeons’ learning curve and experience,
surgical volume, institution characteristics, and the quality
of perioperative care.4 These factors are difficult to assess
and are often not reported in the published literature.THE ROLE OF EVIDENCE SYNTHESIS IN
FORMULATING HIGH QUALITY PRACTICE
GUIDELINES
The ideal evidence-based recommendation should
consider all pertinent evidence. However, with1800 new
citations indexed in MEDLINE each day and 16 million
citations accrued to date,7 it is unrealistic to expect that one
or a few experts would be aware of the totality of evidence
about a particular subject. Furthermore, if experts choose
the evidence they bring to bear in formulating recommen-
dations without explicit and reproducible criteria, they run
the risk of reviewing an incomplete and biased sample of the
available research. Thus, in pursuit of finding the best
evidence for guideline development, a rigorous systematic
review of the literature is paramount. In contrast to tradi-
tional literature reviews, which are nonexhaustive, unsys-
tematic, and can be biased, systematic reviews address a
focused clinical question usingmethods designed to reduce
the likelihood of bias in the identification, selection, critical
appraisal, description, and summary of the totality of the
relevant literature. Compared with the primary studies they
seek to summarize, systematic reviews offer greater preci-
sion in estimating treatment effects, particularly when these
reviews include well-conducted quantitative summary of
the results (ie, meta-analysis) and provide results that are
applicable to a wider range of patients.8
The process of conducting systematic reviews starts by
defining the clinical question in terms of the population,
intervention, comparison, and outcomes. Librarians with
expertise in systematic reviews conduct a sensitive—but not
very specific—search of relevant bibliographic databases.
Reviewers, working independently and in pairs, appraise
studies with predetermined criteria for inclusion and exclu-
sion, assess the quality of studies, and abstract relevant data.
Results are summarized qualitatively or quantitatively. To
ensure high-quality reviews, we monitor and report the
agreement among reviewers by using agreement statistics
(eg,  statistic), contact the authors of primary studies to
ensure correct representation of their results and to ask for
missing data, explore heterogeneity in the results by con-
ducting subgroup and sensitivity analyses, and assess the
potential impact of publication bias on review results
(Table I).
FROM EVIDENCE TO PRACTICE:
FORMULATING CLINICAL
RECOMMENDATIONS
In using evidence to formulate recommendations, it is
helpful for the user of such recommendations to under-
stand how valid, precise, and applicable is the available body
of evidence supporting a recommendation (ie, the quality
of the evidence). High-quality evidence (ie, estimates of
effect for safety and efficacy that are unlikely to change
substantially as new research accumulates) provides greater
confidence in formulating recommendations. Similarly, it is
helpful for the user of practice guidelines to note whether a
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or weak (ie, “may do,” “may not do”).
Multiple systems have been used to rate the quality of
evidence and grade the strength of clinical recommendations.
Thankfully for clinicians and other decisionmakers, there is an
emerging consensus among professional organizations to-
ward using one system, the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) system,
for this purpose.9,10 The GRADE system classifies recom-
mendations as strong (grade 1) or weak (grade 2) and the
quality of the evidence (ie, risk of bias) into one of four
categories (high, moderate, low, or very low). To further
enhance the interpretation and clarity of the recommenda-
tions, guideline developers use the terms “we recommend” to
denote strong recommendations, and the less definitiveword-
ing “we suggest” to denote weak recommendations.
When guideline developers are confident that the de-
sirable effects of adherence to a recommendation outweigh
the undesirable effects, they will make a strong recommen-
dation within the context of a described intervention. Typ-
ically, this requires high- or moderate-quality evidence on
patient-important outcomes, but on occasion, a strong
recommendation can be based on lower-quality evidence.
This may occur when the values and preferences that guide-
line developers bring to bear are such that when consider-
ing even low-quality evidence, they are confident that the
desirable effects of adherence to a recommendation out-
Table I. Conducting a systematic review
Define the question
● Specify inclusion and exclusion criteria
Population
Intervention or exposure
Outcome
Methodology
● Establish a priori hypotheses to explain heterogeneity
● Conduct literature search
● Decide on information sources: databases, experts, funding
agencies, pharmaceutical, companies, hand-searching,
personal files, registries, citation lists of retrieved articles
● Determine restrictions: time frame, unpublished data,
language
● Identify titles and abstracts
Apply inclusion and exclusion criteria
● Apply inclusion and exclusion criteria to titles and abstracts
● Obtain full articles for eligible titles and abstracts
● Apply inclusion and exclusion criteria to full articles
● Select final eligible articles
● Assess agreement on study selection
Extract data
● Data abstraction: participants, interventions, comparison
interventions, study design
● Results
● Methodologic quality
● Assess agreement on validity assessment
Conduct analysis
● Determine method for pooling of results
● Pool results (if appropriate)
● Decide on handling missing data
● Explore heterogeneity, sensitivity, and subgroup analysis
● Explore possibility of publications biasweigh the undesirable effects.A weak recommendation is one for which a guideline
panel concludes that the desirable effects of adherence to a
recommendation probably outweigh the undesirable ef-
fects, but the panel is not confident. Thus, if guideline
developers believe that benefits and downsides are finely
balanced, or appreciable uncertainty exists about this bal-
ance, they offer a weak recommendation. Overall, low- or
very low-quality evidence usually leads to weak recommen-
dations because of uncertainty about the balance between
risks and benefits. Guideline panels may offer weak recom-
mendations even when high-quality evidence is available
because that evidence clearly demonstrates that the benefits
and risks are closely balanced.
As described above, study design and conduct are im-
portant determinants of the quality of evidence (Table
II).11 RCTs allow decisionmakers to draw causal inferences
linking interventions and outcomes with protection against
bias. Therefore, RCTs begin with a “high” quality rating,
whereas observational studies start with a “low” quality
rating. This rating can be downgraded when:
(1) RCTs have serious methodologic limitations; for ex-
ample, lack of allocation concealment and blinding, or
large loss to follow-up;
(2) results were inconsistent among trials,
(3) trials were indirectly relevant; that is, did not directly
apply to the patients, interventions, or outcomes of
interest;
(4) results were imprecise due to small number of studies
and events, or
(5) reporting bias might have affected the estimates (usu-
ally overestimated the beneficial effect or the harmful
effect of treatment).
For example, when evaluating the effectiveness of ac-
cess surveillance on the survival of the vascular access of
hemodialysis we note that (1) there was important incon-
sistency between study results, with 60% of the observed
variability being attributed to true differences in the results
across trials rather than to chance, (2) some RCTs reported
only on the effect of the interventions on access thrombo-
sis, which is a surrogate of the more important outcome,
access loss or abandonment, and (3) only six of 12 studies
evaluated access failure with a total of only 94 events (ie,
accesses lost) in the surveillance group vs 88 events in the
no surveillance group, which produced a wide confidence
interval. Therefore, the overall clinical trial evidence was
downgraded due to inconsistency, indirectness and impre-
cision, respectively; that is, from high-quality evidence to
very low-quality evidence.1
On the other hand, the quality of evidence of observa-
tional studies can be upgraded if (1) a very large treatment
effect was observed, (2) all plausible confounders would
reduce the magnitude of the treatment effect, yet the effect
remains sizable, and (3) a dose-response gradient was
noted. An example of evidence that was upgraded comes
from the comparison of autogenous access with prosthetic
access for hemodialysis. We noted that placing an autoge-
nous access produced a large effect in decreasing the risk of
o und
idence
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of risk), which led to upgrading the quality of the evi-
dence.12
Finally, the GRADE system offers insights into the role
Table II. Grading of Recommendations Assessment, Dev
Rating of evidence
quality Clarity of risk/benefit Des
Strong recommendations
High-quality evidence Benefits clearly outweigh
harms and burdens, or vice
versa
Consis
perf
trial
evid
obse
Moderate-quality
evidence
Benefits clearly outweigh
harms and burdens, or vice
versa
Eviden
trial
(inc
flaw
evid
evid
obse
Low-quality evidence Benefits clearly outweigh
harms and burdens, or vice
versa
Eviden
outc
stud
cont
or in
Very low-quality
evidence (very rarely
applicable)
Benefits clearly outweigh
harms and burdens, or vice
versa
Eviden
outc
clini
evid
Weak recommendations
High-quality evidence Benefits closely balanced with
harms and burdens
Consis
perf
trial
evid
obse
Moderate-quality
evidence
Benefits closely balanced with
harms and burdens
Eviden
trial
(inc
flaw
evid
evid
obse
Low-quality evidence Uncertainty in the estimates
of benefits, harms, and
burdens; benefits may be
closely balanced with
harms and burdens
Eviden
outc
stud
cont
or in
Very low-quality
evidence
Major uncertainty in the
estimates of benefits,
harms, and burdens;
benefits may or may not be
balanced with harms and
burdens
Eviden
outc
obse
evid
Modified from Schunemann HJ et al.11
aExceptionally strong evidence from unbiased observational studies includes
and consistent and (2) evidence where all potential biases may be working t
effect is likely to be larger than that suggested by the study data, and (3) evof values and preferences when it disentangles the strengthof recommendations from the quality of the evidence and
when it encourages statements about the underlying values
and preferences relevant to the recommendations. For ex-
ample, the vascular access committee issued a strong rec-
ent and Evaluation guidelines
on of supporting evidence Implications
evidence from well-
d randomized controlled
xceptionally strong
from unbiased
nal studiesa
Recommendation can apply to most
patients in most circumstances.
Further research is very unlikely
to change our confidence in the
estimate of effect.
m randomized controlled
important limitations
ent results, methodologic
irect or imprecise
, or unusually strong
from unbiased
nal studies
Recommendation can apply to most
patients in most circumstances.
Further research (if performed) is
likely to have an impact on our
confidence in the estimate of
effect and may change the
estimate.
r at least one critical
from observational
om randomized
trials with serious flaws,
t evidence
Recommendation may change when
higher quality evidence becomes
available. Further research is very
likely to have an important
impact on our confidence in the
estimate of effect and is likely to
change the estimate.
r at least one of the critical
from unsystematic
servations or very indirect
Recommendation may change when
higher quality evidence becomes
available; any estimate of effect
for at least one critical outcome,
is very uncertain.
evidence from well-
d randomized controlled
xceptionally strong
from unbiased
nal studies.
The best action may differ
depending on circumstances or
patient or societal values. Further
research is very unlikely to change
our confidence in the estimate of
effect.
m randomized controlled
important limitations
ent results, methodologic
irect or imprecise
, or unusually strong
from unbiased
nal studies
Alternative approaches likely to be
better for some patients under
some circumstances. Further
research (if performed) is likely to
have an important impact on our
confidence in the estimate of
effect and may change the
estimate.
r at least one critical
from observational
om randomized
trials with serious flaws,
t evidence
Other alternatives may be equally
reasonable. Further research is
very likely to have an important
impact on our confidence in the
estimate of effect and is likely to
change the estimate.
r at least one critical
from unsystematic clinical
ns or very indirect
Other alternatives may be equally
reasonable. Any estimate of effect,
for at least one critical outcome,
is very uncertain.
idence from studies that yield estimates of the treatment effect that are large
erestimate an apparent treatment effect, and therefore, the actual treatment
where a dose-response gradient exists.elopm
cripti
tent
orme
s or e
ence
rvatio
ce fro
s with
onsist
s, ind
ence)
ence
rvatio
ce fo
ome
ies, fr
rolled
direc
ce fo
omes
cal ob
ence
tent
orme
s or e
ence
rvatio
ce fro
s with
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direc
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(1) evommendation for using distal arm autogenous access as a
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dence for this recommendation was considered to have very
low quality because most of the studies were nonrandom-
ized (80 of 83), the study cohorts were prognostically
imbalanced at baseline, outcome assessors were mostly
unblinded, apparent reporting bias was present, and results
were inconsistent among studies to the extent that the
proportion of heterogeneity that is not attributable to
chance in most outcomes 50% and often 90%.
These limitations in the quality of evidence notwith-
standing, the committee issued a strong recommendation
because they placed higher value on optimizing patient-
important outcomes such as preventing death, access infec-
tion, local complications, and achieving a longer period of
time with successful dialysis; all were features thought to be
more associated with the autogenous access. In recom-
mending distal upper extremity access sites despite the very
low quality evidence, they also placed high value on the
preservation of proximal veins or future access placement.
The committee placed lower value on some of the charac-
teristics of the prosthetic access such as higher reimburse-
ment for placement, ready off-the-shelf availability, and
shorter time to first use for dialysis. Hence, the guideline
authors made a strong recommendation when they as-
sumed that the pertinent values and preferences across a
broad range of informed patients are consistent with the
recommended action.
THE FUTURE
The Society for Vascular Surgery belongs to a select but
expanding groupof professional organizations that has endorsed
an approach that is the state-of-the-art in guideline formulation
and grading. This position is not without challenges. The
GRADE Working Group (www.gradeworkinggroup.org)
is identifying the best approaches to the grading of diag-
nostic recommendations. There is considerable uncertainty
on how to incorporate considerations about resource utili-
zation and societal priorities in health care. Also, mecha-
nisms to incorporate patient preferences into guideline
formulation are in their infancy.
Other challenges for the Society involve the use of the
guidelines to inform policies in support of quality improve-
ment efforts. For example, it is plausible that strongly
recommended procedures could lead to process-of-care
parameters that can be part of quality assessment and
incentive schemes. Weak recommendations, on the otherhand, may indicate areas not ready for quality improve-
ment. How the Society, and other organizations, can move
from guideline formulation to practice implementation
represents yet another frontier in this field.
In future articles, we will keep the vascular surgery
community abreast of developments in the methodology of
guideline development while we continue to improve on
the procedures we have began to use in response to users’
feedback.
REFERENCES
1. Casey E, Murad MH, Rizvi A, Sidawy AN, Elamin MB, Flynn D, et al.
Surveillance of arteriovenous hemodialysis access: a systematic review
and meta-analysis. J Vasc Surg 2008;48(Suppl):48S-54S.
2. Poolman RW, Petrisor BA, Marti RK, Kerkhoffs GM, Zlowodzki M,
Bhandari M. Misconceptions about practicing evidence-based orthope-
dic surgery. Acta Orthopaedica 2007;78:2-11.
3. Wente MN, Seiler CM, Uhl W, Buchler MW. Perspectives of evidence-
based surgery. Dig Surg 2003;20:263-9.
4. Devereaux PJ, Bhandari M, Clarke M, Montori VM, Cook DJ, Yusuf S,
et al. Need for expertise based randomised controlled trials [see com-
ment]. BMJ 2005;330:88.
5. LevineM, HaslamD,Walter S, Cumming R, Lee H, Haines T, et al. In:
Guyatt G, Rennie D, editors. Users’ guides to the medical literature: a
manual for evidence-based clinical practice. Chicago, Ill: AMA Press;
2002. p. 81-100.
6. Wells G, Shea B, O’Connell D, Peterson J, Welch V, LososM, et al. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandom-
ised studies in meta-analyses. http://www.ohri.ca/programs/clinical_
epidemiology/oxford.htm. Accessed: Feb 15, 2007.
7. National Library of Medicine; Detailed indexing statistics: 1965-2006.
http://www.nlm.nih.gov/bsd/index_stats_comp.html. Accessed: Feb
15, 2007.
8. Oxman A, Guyatt G, Cook D, Montori V. Summarizing the evidence.
In: Guyatt G, Rennie D, editorss. Users’ guides to the medical litera-
ture: a manual for evidence-based clinical practice. Chicago, Ill: AMA
Press; 2002. p. 155-73.
9. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.
Grading quality of evidence and strength of recommendations. BMJ
2004;328:1490.
10. GRADE Working Group. http://www.gradeworkinggroup.org/society/
index.htm. Accessed: Nov 1, 2007.
11. Schunemann H, Jaeschke R, Cook D, Bria W, El-Solh A, Ernst A, et al.
ATS Documents Development and Implementation Committee. An
official ATS statement: grading the quality of evidence and strength of
recommendations in ATS guidelines and recommendations. Am J Re-
spir Crit Care Med 2006;174:605-14.
12. Murad MH, Elamin MB, Sidawy AN, Malaga G, Rizvi A, Flynn D, et al.
Autogenous vs prosthetic vascular access for hemodialysis: a systematic
review and meta-analysis. J Vasc Surg 2008;48(suppl):34S-47S.Submitted Aug 6, 2008; accepted Aug 13, 2008.
